Highlights
- •68Ga-DOTATATE-PET has a role in imaging MTC patients with suspected recurrence.
- •68Ga-DOTATATE-PET may be complementary to 18F-FDG-PET when imaging MTC patients for recurrence.
- •The cost and technicalities of 68Ga-DOTATATE-PET should be considered.
Abstract
Background
Many patients with Medullary Thyroid Cancer (MTC) will have persistent or recurrent
disease after surgery requiring lifelong surveillance with imaging and tumor markers.
The objective of this study is to evaluate the efficacy of 68Ga-DOTATATE-PET (or 68Ga labelled equivalent radiopharmaceutical) versus 18F-FDG-PET for detecting persistent and/or metastatic recurrent MTC.
Methods
Relevant studies were identified by conducting searches in Embase and PubMed and five
studies were included in the final review.
Results
Five studies investigated per-patient sensitivity of 18F-FDG-PET and 68Ga-DOTATATE-PET in MTC patients. Four studies investigated the correlation between
calcitonin and number of lesions detected by 18F-FDG-PET and 68Ga-DOTATATE-PET, and three investigated the correlation between CEA and number of
lesions detected by 18F-FDG-PET and 68Ga-DOTATATE-PET. There was no significant difference in number of lesions detected
by 18F-FDG -PET compared with 68Ga-DOTATATE-PET.
Conclusions
When compared directly to 18F-FDG-PET, there is a general trend towards favoring 68Ga-DOTATATE-PET in per-patient sensitivities, and incidence of lesion detection.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Medullary thyroid carcinoma: an update on imaging.J Thyroid Res. 2019; 2019: 1-17https://doi.org/10.1155/2019/1893047
- Revised American thyroid association guidelines for the management of medullary thyroid carcinoma.Pediatrics. 2018; 142e20183062https://doi.org/10.1542/peds.2018-3062
- Medullary thyroid carcinoma: management of lymph node metastases.J Natl Compr Cancer Netw. 2010; 8: 549-556https://doi.org/10.6004/jnccn.2010.0042
- Medullary thyroid carcinoma: management of lymph node metastases.Curr Treat Options Oncol. 2005; 6: 347-354https://doi.org/10.1007/s11864-005-0038-6
- Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.Eur J Nucl Med Mol Imag. 2012; 39: 569-580https://doi.org/10.1007/s00259-011-2031-6
- Revised American thyroid association guidelines for the management of medullary thyroid carcinoma.Thyroid. 2015; 25: 567-610https://doi.org/10.1089/thy.2014.0335
- Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis.BMJ. 2001; 323: 101-105https://doi.org/10.1136/bmj.323.7304.101
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.Cochrane Database Syst Rev. 2019; (October)https://doi.org/10.1002/14651858.ED000142
- Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.Eur J Nucl Med Mol Imag. 2010; 37: 49-57https://doi.org/10.1007/s00259-009-1204-z
- Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma.Nucl Med Commun. 2012; 33: 766-774https://doi.org/10.1097/MNM.0b013e3283541157
- Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.Nucl Med Commun. 2015; 36: 242-250https://doi.org/10.1097/MNM.0000000000000240
- The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow‐up of medullary thyroid cancer.J Med Imaging Radiat Oncol. 2020; 64: 756-761https://doi.org/10.1111/1754-9485.13081
- Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.Biomed Pharmacother. 2008; 62: 139-146https://doi.org/10.1016/j.biopha.2007.07.011
- Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.Clin Endocrinol. 2001; 54: 641-649https://doi.org/10.1046/j.1365-2265.2001.01175.x
- SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?.Eur J Nucl Med Mol Imag. 2017; 44: 1692-1694https://doi.org/10.1007/s00259-017-3757-6
- Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.Surgery. 1997; 122: 1049-1061https://doi.org/10.1016/S0039-6060(97)90208-7
- Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.J Nucl Med. 2007; 48: 501-507https://doi.org/10.2967/jnumed.106.036681
- Gallium-68 dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.Hellenic J Nucl Med. 2015; 18: 19-24https://doi.org/10.1967/s002449910163
- Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.J Clin Endocrinol Metab. 2014; 99: 3263-3274https://doi.org/10.1210/jc.2013-3483
- 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.Int J Endocr Oncol. 2018; 5: IJE04https://doi.org/10.2217/ije-2017-0005
- Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE.EJNMMI Radiopharm Chem. 2021; 6: 1https://doi.org/10.1186/s41181-020-00114-9
Article info
Publication history
Published online: March 29, 2022
Accepted:
March 25,
2022
Received in revised form:
February 15,
2022
Received:
November 12,
2021
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
